HNSCC

Oncology·MeSH: Squamous Cell Carcinoma of Head and Neck

32 drugs in development·20 companies·11 clinical trials

Drug Pipeline by Phase

Phase 3(3)

Phase 2(17)

Drug	Company
carbon nanoparticle iron	NYMOX PHARMACEUTICAL CORP (NYMXF)
cemiplimab	West Pharmaceutical Services Inc. (WST)
Cetuximab	ImmunityBio, Inc. (IBRX)
cmp-001	CHECKMATE PHARMACEUTICALS, INC. (CMPI)
CX-2029	CytomX Therapeutics, Inc. (CTMX)
EOS-448	iTeos Therapeutics, Inc. (ITOS)
fdc fianlimab+cemiplimab	West Pharmaceutical Services Inc. (WST)
gedeptin	GeoVax Labs, Inc. (GOVX)
NAI	FATE THERAPEUTICS INC (FATE)
NAI	Amneal Pharmaceuticals, Inc. (AMRX)
PD-L1 t-haNK	FATE THERAPEUTICS INC (FATE)
PD-L1 t-haNK	Amneal Pharmaceuticals, Inc. (AMRX)
Sacituzumab Govitecan	Amneal Pharmaceuticals, Inc. (AMRX)
STRO-002 (luveltamab tazevibulin, luvelta)	SUTRO BIOPHARMA, INC. (STRO)
tipifarnib	Kura Oncology, Inc. (KURA)
versamune hpv	PDS Biotechnology Corp (PDSB)
vidutolimod	CHECKMATE PHARMACEUTICALS, INC. (CMPI)

Phase 1(8)

Drug	Company
BI 770371	Amneal Pharmaceuticals, Inc. (AMRX)
CLD-201 (SuperNova™ / SNV1)	Calidi Biotherapeutics Inc. (CLDI)
STRO-001	SUTRO BIOPHARMA, INC. (STRO)
STRO-003	SUTRO BIOPHARMA, INC. (STRO)
STRO-004	SUTRO BIOPHARMA, INC. (STRO)
stro-006	SUTRO BIOPHARMA, INC. (STRO)
stro-227	SUTRO BIOPHARMA, INC. (STRO)
tagmokitug	Coherus Oncology, Inc. (CHRS)

Phase 1/Phase 2(2)

Drug	Company
GTAEXS617	RECURSION PHARMACEUTICALS, INC. (RXRX)
micvotabart pelidotin	Pyxis Oncology, Inc. (PYXS)

Phase 2/Phase 3(2)

Drug	Company
Actimab-A	Actinium Pharmaceuticals, Inc. (ATNM)
inbrx-106	Inhibrx Biosciences, Inc. (INBX)

BioSniper tracks 32 drugs in development for HNSCC across 20 companies.

There are 11 clinical trials targeting HNSCC tracked by BioSniper.

Full trial data, competitive analysis, and AI-powered pipeline tracking.